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Efficacy and Safety of Vorapaxar in Non–ST-Segment Elevation Acute
Coronary Syndrome Patients Undergoing Noncardiac Surgery
Sean van Diepen, MD, MSc; Pierluigi Tricoci, MD, PhD, MHS; Mohua Podder, PhD; Cynthia M. Westerhout, PhD; Philip E. Aylward, MD;
Claes Held, MD, PhD; Frans Van de Werf, MD; John Strony, MD; Lars Wallentin, MD; David J. Moliterno, MD; Harvey D. White, DSc;
Kenneth W. Mahaffey, MD; Robert A. Harrington, MD; Paul W. Armstrong, MD
Background-—Perioperative antiplatelet agents potentially increase bleeding after non–ST-segment elevation (NSTE) acute
coronary syndromes (ACS). The protease-activated receptor 1 antagonist vorapaxar reduced cardiovascular events and was
associated with increased bleeding versus placebo in NSTE ACS, but its efficacy and safety in noncardiac surgery (NCS) remain
unknown. We aimed to evaluate ischemic, bleeding, and long-term outcomes of vorapaxar in NCS after NSTE ACS.
Methods and Results-—In the TRACER trial, 2202 (17.0%) patients underwent major or minor NCS after NSTE ACS over 1.5 years
(median); continuing study treatment perioperatively was recommended. The primary ischemic end point for this analysis was
cardiovascular death, myocardial infarction, stent thrombosis, or urgent revascularization within 30 days of NCS. Safety outcomes
included 30-day NCS bleeding and GUSTO moderate/severe bleeding. Overall, 1171 vorapaxar and 1031 placebo patients
underwent NCS. Preoperative aspirin and thienopyridine use was 96.8% versus 97.7% (P=0.235) and 89.1% versus 86.1%
(P=0.036) for vorapaxar versus placebo, respectively. Within 30 days of NCS, no differences were observed in the primary ischemic
end point between vorapaxar and placebo groups (3.4% versus 3.9%; adjusted odds ratio 0.81, 95% CI 0.50 to 1.33, P=0.41).
Similarly, no differences in NCS bleeding (3.9% versus 3.4%; adjusted odds ratio 1.41, 95% CI 0.87 to 2.31, P=0.17) or GUSTO
moderate/severe bleeding (4.2% versus 3.7%; adjusted odds ratio 1.15, 95% CI, 0.72 to 1.83, P=0.55) were observed. In a 30-day
landmarked analysis, NCS patients had a higher long-term risk of the ischemic end point (adjusted hazard ratio 1.62, 95% CI 1.33
to 1.97, P<0.001) and GUSTO moderate/severe bleeding (adjusted hazard ratio 5.63, 95% CI 3.98 to 7.97, P<0.001) versus
patients who did not undergo NCS, independent of study treatment.
Conclusion-—NCS after NSTE ACS is common and associated with more ischemic outcomes and bleeding. Vorapaxar after NSTE
ACS was not associated with increased perioperative ischemic or bleeding events in patients undergoing NCS. ( J Am Heart Assoc.
2015;4:e002546 doi: 10.1161/JAHA.115.002546)
Key Words: coronary disease • hemorrhage • noncardiac surgery • non–ST-segment elevation acute coronary syndromes
• surgery • vorapaxar
A fter an acute coronary syndromes (ACS) or percuta-neous coronary interventions, up to one-third of patients
require noncardiac surgery (NCS).1–3 Importantly, a previous
ACS is an important risk factor for perioperative major
adverse cardiac events.4–6 Although the perioperative use of
antiplatelet therapies has been reported to reduce major
adverse cardiac events in high-risk NCS patients, it may also
increase bleeding complications.7–10 In the Thrombin Recep-
tor Antagonist for Clinical Event Reduction in Acute Coronary
Syndrome (TRACER) trial, the protease-activated receptor 1
From the Divisions of Critical Care and Cardiology (S.v.D.) and Canadian VIGOUR Centre (S.v.D., M.P., C.M.W., P.W.A.), University of Alberta, Edmonton, Alberta,
Canada; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (P.T.); SAHMRI, Flinders University and Medical Centre, Adelaide, Australia
(P.E.A.); Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala, Sweden (C.H., L.W.); Department of Cardiology, University of Leuven, Belgium
(F.V.W.); Merck, Whitehouse Station, NJ (J.S.); Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY (D.J.M.); Green Lane
Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Stanford University, Stanford, CA (K.W.M., R.A.H.); Division of Cardiology, University of
Alberta, Edmonton, Alberta, Canada (P.W.A.).
Accompanying Tables S1 through S4 are available at http://jaha.ahajournals.org/content/4/12/e002546/suppl/DC1
Correspondence to: Sean van Diepen, MD, MSc, 2C2 Cardiology Walter MacKenzie Center, University of Alberta Hospital, 8440-11 St. Edmonton, Alberta, Canada
T6G 2B7. E-mail: sv9@ualberta.ca
Received August 10, 2015; accepted October 30, 2015.
ª 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is
not used for commercial purposes.
DOI: 10.1161/JAHA.115.002546 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 at University of Kentucky--Lexington on June 13, 2016http://jaha.ahajournals.org/Downloaded from 
antagonist vorapaxar reduced the secondary end point of
cardiovascular death, myocardial infarction, or stroke but
increased the risk of bleeding in patients with non–ST-
segment elevation (NSTE) ACS.11 The long biologic half-life of
vorapaxar coupled with its recent US Food and Drug
Administration regulatory approval for use in patients with a
previous myocardial infarction without a previous stroke,
transient ischemic attack, or intracranial bleeding creates
unique questions regarding its optimal perioperative use. The
efficacy and safety of vorapaxar in patients undergoing NCS
after NSTE ACS have not been explored.12
Although the 30-day perioperative risks and clinical
outcomes in NCS have been described in the percutaneous
coronary intervention era, the long-term outcomes associated
with major and minor NCS after NSTE ACS remain
unclear.1,3,13,14 Accordingly, in the TRACER trial, we evaluated
(1) the 30-day perioperative and long-term efficacy and safety
of vorapaxar in patients undergoing major and minor NCS as
they relate to the type and timing of surgery and (2) the long-
term prognosis associated with NCS after NSTE ACS.
Methods
The TRACER trial (ClinicalTrials.gov identifier NCT00527943)
was a multicenter, double-blind, randomized placebo-con-
trolled study that evaluated vorapaxar in 12 944 NSTE ACS
patients in 37 countries. The methods and results of this
study have been previously described.11,12 Briefly, patients
were enrolled if they presented to a hospital within 24 hours
of coronary ischemia symptoms with ≥1 of the following:
creatinine kinase-MB or troponin level higher than the upper
limit of normal; new ST-segment depression >0.1 mV; or
transient (<30 minutes) ST-segment elevation >0.1 mV in 2
contiguous leads. Patients also required ≥1 of the following
additional risk factors: age ≥55 years; prior myocardial
infarction, percutaneous coronary intervention, or coronary
artery bypass grafting; diabetes mellitus; or peripheral arterial
disease. Randomized patients received vorapaxar or a
matching placebo, and the intention to use a glycoprotein
IIb/IIIa inhibitor and a parenteral direct thrombin inhibitor was
stratified. The study was approved by the appropriate national
and institutional regulatory and ethics committees, and all
participants provided informed consent.
Study Population and Covariates
The present analysis included all patients in the TRACER trial
who were admitted with an NSTE ACS and treated either with
a coronary stent or with medical therapy alone and subse-
quently underwent either major or minor NCS. Patients who
underwent coronary artery bypass grafting were specifically
excluded: vorapaxar outcomes in this patient population have
been previously described.15 The TRACER case report form
contained the type, date, and reasons for NCS procedure as
entered by local study personnel. The study authors examined
all NCS data entries and classified them as either major or
minor surgery. Major surgical procedures were defined using
the American Heart Association/American College of Cardi-
ology definitions of intermediate- and high-risk procedures.16
Major procedures were further classified by surgical site
according to prior categorization as follows: abdominal,
thoracic, orthopedic and spinal, vascular, pelvic (urological
and gynecological), intracranial neurologic, and head and neck
surgeries.17–19 Minor surgical procedures were similarly
identified using guideline definitions of low-risk procedures
and included endoscopic, superficial, cataract, breast, ambu-
latory, percutaneous, or dental procedures.16 Repeat coronary
angiograms, percutaneous coronary interventions, and car-
diac surgical procedures were excluded. If a patient under-
went a major and minor surgical procedure within 30 days,
the major procedure was hierarchically selected as the index
procedure to avoid an excess attributable risk to minor
procedures (eg, a bronchoscopy preceding a lobectomy).
The timing of NCS after NSTE ACS events was a priori
categorized as follows: ≤30, >30 to 180, >180 days to
1 year, and >1 year. The TRACER case report form coded for
the preoperative use of all cardiac medications. Given the long
biologic half-life of vorapaxar, the study protocol recom-
mended study drug continuation through NCS procedures.12
The timing and reasons for interruptions were recorded in the
case report form by local study personnel. The primary
analysis of this study compared clinical end points in
vorapaxar- versus placebo-treated patients who underwent
NCS. A secondary analysis evaluated the long-term clinical
outcomes in NSTE ACS patients who underwent NCS
regardless of treatment assignment. A sensitivity analysis
limited to participants who were receiving perioperative
treatment was also performed.
Outcomes
The primary ischemic end point for this analysis was the
incidence of 30-day perioperative cardiovascular death,
nonfatal myocardial infarction, stent thrombosis, or urgent
revascularization. The secondary ischemic end points of
interest included the TRACER trial primary end point (cardio-
vascular death, myocardial infarction, recurrent ischemia with
rehospitalisation, or stroke), the individual components of the
primary ischemic end point, all-cause mortality, stroke, and
the incidence of the composite primary outcome among 30-
day NCS survivors through study follow-up. The primary
bleeding end point was the 30-day incidence of perioperative
NCS bleeding defined as any GUSTO (Global Utilization of
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Strategies to Open Occluded Arteries) or TIMI (Thrombolysis
In Myocardial Infarction) bleeding associated with the NCS.
For example, a surgical incision site hematoma would qualify
as NCS bleeding but spontaneous epistaxis would not. The
secondary bleeding end points included all 30-day perioper-
ative GUSTO moderate or severe bleeding, TIMI major or
minor bleeding, and TIMI clinical significant bleeding. All
clinical end points were adjudicated by a clinical events
committee.
Statistical Methods
Patient and procedural characteristics, concomitant treat-
ment, and in-hospital procedures are reported as medians
(25th, 75th percentiles) for continuous variables and as
percentages for discrete variables. The Wilcoxon rank sum
test and v2 test were applied, respectively, to test differences
between groups, including 30-day outcomes. Kaplan–Meier
estimates were reported for 2-year follow-up, and differences
among groups were tested by using the log-rank test (when
proportional hazard assumptions were met).
The associations of vorapaxar versus placebo with the 30-
day NCS primary end point and safety end points for the NCS
patients (intent-to-treat) were examined through multivariable
logistic regression. These associations were examined in
patients who were event free at the time of surgery. Study
treatment–related analyses were based on the intention-to-
treat assumption, unless otherwise stated. Associations with
30-day events were reported as odds ratios (ORs) with 95%
CIs. Sensitivity analyses were also carried out on patients who
were receiving treatment during surgery, including 901
vorapaxar- and 819 placebo-treated patients.
To compare long-term prognosis between NSTE ACS
patients who did not undergo NCS with those who did
undergo NCS and survived 30 days postrandomization and
postoperatively, respectively, time-to-event analyses were
performed. Hazard ratios (HRs) and 95% CIs were calculated
using Cox proportional hazards regression, including NCS as a
time-dependent covariate and with the adjustment of baseline
covariates and randomized stratification factors (Table S1).
SAS software version 9.4 (SAS Institute) was used to
perform statistical analyses. P-values were not adjusted for
multiple comparisons.
Results
In the TRACER trial, 2202 (17.0%) of 12 944 patients
underwent NCS after randomization during a median follow-
up of 1.5 years. A total of 1312 (10.1%) patients underwent
cardiac surgery after randomization and were excluded from
the study. Baseline characteristics of patients who did and did
not undergo NCS are provided in Table S2. Briefly, patients
who underwent NCS were more likely to be older, have a
higher body mass index, have more comorbidities, and have a
lower creatinine clearance and were more frequently in the
vorapaxar treatment group. There were no differences
between the 2 groups in revascularization strategies after
the index NSTE ACS. The incidence of NCS varied by study
region as follows: North America 25.8%, South America
12.6%, Western Europe 16.8%, Eastern Europe 12.8%, Asia
19.6%, and Australia/New Zealand 30.4%.
Study participants who underwent NCS were followed for a
median of 565 days. Among the 2202 NCS procedures, 474
(21.5%) patients had major and 1728 (78.5%) had minor
surgical procedures. The proportion of NCS procedures
relative to the timing after the index NSTE ACS was
categorized as ≤30, >30 to 180, >180 days to 1 year, and
>1 year and distributes as 18.5%, 30.9%, 27.2%, and 23.5%,
respectively.1,16,20 The preoperative use of aspirin and
thienopyridines was 97.2% and 87.7%, respectively, and
21.7% of patients stopped the study drug a median of 14.0
(3.0, 62.0) days preoperatively.
The baseline characteristics of NCS patients by treatment
assignment are provided in Table 1. Vorapaxar- and placebo-
treated patients were well balanced by age, sex, medical
history, index NSTE ACS revascularization, major versus minor
surgery, and surgical timing. There were no differences in
either the number of vorapaxar- and placebo-treated patients
in whom the study drug was held preoperatively (23.1% versus
20.2%, P=0.102) or in the median times between the last
study drug dose and surgery (13 versus 15 days, P=0.431).
Vorapaxar-treated patients were more likely to receive
thienopyridines preoperatively (89.1% versus 86.1%,
P=0.036). Preoperative aspirin and b-blocker utilization was
similar between groups. The incidences of NCS preoperative
GUSTO moderate or severe (7.3% versus 4.8%, P=0.011) and
TIMI clinically significant (25.4% versus 17.7%, P<0.001)
bleeding were higher among vorapaxar-treated NCS patients,
but no treatment-related differences were observed in the
time between bleeding events and NCS.
Outcomes of NCS Patients by Treatment
Assignment
The 30-day incidence of the primary ischemic outcome of
cardiovascular mortality, nonfatal myocardial infarction, stent
thrombosis, or urgent revascularization was similar in vora-
paxar- and placebo-treated NCS patients (3.4% versus 3.9%,
P=0.562). Additionally, no differences in the individual
components of the 30-day ischemic end point (Figure 1;
P>0.05 for all) or the TRACER end point (4.4% versus 4.3%,
P=0.843) were observed. The primary bleeding end point of
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Table 1. Baseline Characteristics of NCS Patients by Treatment Assignment
Characteristics Vorapaxar (n=1171) Placebo (n=1031) P Value
Age, y, median (IQR) 66.0 (60.0–74.0) 65 (59.0–73.0) 0.073
Female, n (%) 335 (28.6) 96 (28.7) 0.958
Racial or ethics group, n (%)
White 1007 (86.3) 891 (86.7) 0.701
Black 29 (2.5) 25 (2.4)
Asian 100 (8.6) 86 (8.4)
Other 31 (2.7) 26 (2.5)
Body weight, kg, median (IQR) 81.0 (70.0–94.1) 82.0 (70.5–95.0) 0.125
Medical history, n (%)
Hypertension 846 (72.2) 766 (74.3) 0.278
Dyslipidemia 797 (68.1) 693 (67.2) 0.651
Diabetes mellitus 428 (36.6) 371 (36.0) 0.783
Current tobacco use 264 (22.5) 256 (24.8) 0.208
Myocardial infarction 382 (32.6) 348 (33.8) 0.573
Percutaneous coronary intervention 331 (28.3) 294 (28.5) 0.886
Coronary artery bypass grafting 200 (17.1) 190 (18.4) 0.408
Heart failure 157 (13.4) 168 (16.3) 0.055
Atrial fibrillation 71 (6.1) 65 (6.3) 0.814
Stroke or transient ischemic attack 93 (7.9) 93 (9.0) 0.364
Peripheral arterial disease 120 (10.2) 114 (11.1) 0.539
Variables at NSTE ACS presentation
Heart rate, bpm, median (IQR) 70 (61–80) 69 (61–79) 0.824
Systolic blood pressure, mm Hg, median (IQR) 131 (118–146) 130 (118–146) 0.759
Diastolic blood pressure, mm Hg, median (IQR) 72 (65–81) 74 (65–83) 0.235
Hemoglobin, g/L, median (IQR) 138 (126–149) 140 (126–150) 0.143
Creatinine clearance, lmol/L, median (IQR) 87.8 (67.1–112.2) 89.1 (66.3–118.0) 0.115
Positive troponin or CK-MB, n (%) 1101 (94.4) 978 (95.2) 0.398
Electrocardiographic findings, n (%)
ST-segment depression 353 (30.1) 296 (28.7) 0.461
ST-segment elevation 60 (5.1) 44 (4.3) 0.345
TIMI risk score, n (%) 0.520
0–2 6 (0.5) 5 (0.5)
3–4 515 (44.0) 474 (46.0)
5–7 650 (55.5) 552 (53.5)
Killip class, n/N (%) 0.442
I 1090/1166 (93.5) 951 (92.5)
II 55/1166 (4.7) 60/1028 (5.8)
III/IV 21/1166 (1.8) 17/1028 (1.7)
Region of enrollment, n (%) 0.750
North America 399 (34.1) 355 (34.4)
South America 50 (4.3) 38 (3.7)
Continued
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30-day NCS bleeding was similar for vorapaxar- and placebo-
treated patients (3.9% versus 3.4%, P=0.507). Similarly, no
differences in the incidence of all GUSTO moderate/severe,
TIMI major/minor, or TIMI clinically significant bleeding were
observed (P>0.05 for all).
After multivariable adjustment, the 30-day associations
between treatment assignment and the primary ischemic end
point (adjusted OR 0.81, 95% CI, 0.50 to 1.33, P=0.412)
(Figure 1), TRACER end point (adjusted OR 1.01, 95% CI, 0.64
to 1.60, P=0.953), NCS bleeding (adjusted OR 1.41, 95% CI,
0.87 to 2.31, P=0.165), GUSTO moderate or severe bleeding
(adjusted OR 1.15, 95% CI, 0.72 to 1.83, P=0.551), TIMI
clinically significant bleeding (adjusted OR 1.17, 95% CI, 0.84
to 1.65, P=0.355), and TIMI major or minor bleeding (adjusted
OR 1.07, 95% CI, 0.67 to 1.70, P=0.768) remained nonsignif-
icant. In a sensitivity analysis, no differences between
treatment groups in the adjusted study outcomes were
observed among on-treatment study patients (Table 2). No
differences in the adjusted end points were observed between
vorapaxar- versus placebo-treated NCS patients between
postoperative day 30 through the end of study follow-up
(Table S3).
Clinical Outcomes by Surgical Timing, Surgical
Type, and Revascularization Strategy
The timing of surgery after NSTE ACS ≤30, >30 to 180,
>180 days to 1 year, and >1 year was 20.9%, 32.2%, 26.4%,
and 20.5% for minor procedures and 9.7%, 26.2%, 30.2%, and
34.0% for major procedures, respectively. No significant
interactions between study treatment and clinical outcomes
were observed for surgical timing, revascularization strategies
after the index NSTE ACS, or major versus minor surgery;
thus, study treatment groups were pooled (Figure 2,
Table S4). The adjusted 30-day post-NCS risk of cardiovas-
cular mortality, nonfatal myocardial infarction, stent
Table 1. Continued
Characteristics Vorapaxar (n=1171) Placebo (n=1031) P Value
Western Europe 467 (39.9) 427 (41.4)
Eastern Europe 93 (7.9) 83 (8.0)
Asia 93 (7.9) 81 (7.9)
Australia or New Zealand 69 (5.9) 47 (4.6)
Drugs at time of NSTE ACS, n (%)
Thienopyridine 1043 (89.1) 888 (86.1) 0.036
Aspirin 1134 (96.8) 1007 (97.7) 0.235
b-Blocker 889 (75.9) 805 (78.1) 0.230
NSTE ACS revascularization, n (%)
Medical therapy 418 (35.7) 402 (39.0) 0.186
Bare-metal stent 298 (25.4) 234 (22.7)
Drug-eluting stent 455 (38.9) 395 (38.3)
Type of surgery, n (%)
Major 247 (21.1) 227 (22.0) 0.599
Minor 924 (78.9) 804 (78.0)
Timing of surgery after randomization, d median (IQR) 180 (51–341) 195 (61–370) 0.053
≤30 d 226 (19.3) 181 (17.6) 0.165
>30 d to 6 mo 362 (30.9) 318 (30.8)
>6 mo to 1 y 330 (28.2) 270 (26.2)
>1 y 253 (21.6) 262 (25.4)
Timing of surgery relative to study drug, n (%)
Surgery before last dose 901 (76.9) 819 (79.8) 0.102
Surgery after last dose 270 (23.1) 207 (20.2)
Time between surgery and last dose, d median (IQR) 13.0 (3.0–52.0) 15.0 (3.0–92.0) 0.431
CK-MB indicates creatinine kinase-MB; NCS, noncardiac surgery; NSTE ACS, non–ST-segment elevation acute coronary syndrome; TIMI, Thrombolysis In Myocardial Infarction.
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thrombosis, or urgent revascularization was highest among
patients undergoing surgery within 30 days of the index NSTE
ACS. Perioperative 30-day NCS bleeding was numerically
lower than GUSTO moderate/severe, TIMI clinically signifi-
cant, or TIMI major/minor bleeding. Compared with patients
undergoing NCS within 30 days of the index NSTE ACS, the
adjusted risk of perioperative NCS bleeding was higher
between >30 and 180 days, but no significant difference was
observed beyond 180 days. The risk of TIMI clinically
significant and major or minor bleeding was significantly
lower in patients undergoing NCS after 30 days. There were
no observed differences in the adjusted 30-day risk of the
primary ischemic outcome between major and minor surg-
eries, but the risk of 30-day NCS-related bleeding and GUSTO
moderate or severe bleeding was higher for major surgical
procedures. The risk-adjusted 30-day ischemic outcomes for
Figure 1. Adjusted associations between study treatment and 30-day clinical outcomes in NCS patients.
No treatment-related ischemic or bleeding differences were observed. GUSTO indicates Global Utilization of
Strategies to Open Occluded Arteries; NCS, noncardiac surgery; OR, odds ratio; TIMI, Thrombolysis In
Myocardial Infarction.
Table 2. Unadjusted and Adjusted Vorapaxar Versus Placebo 30-Day Perioperative Outcomes in the On-Treatment Population
Endpoints
Observed Events*
Adjusted OR (95% CI) P ValueVorapaxar Placebo
Primary ischemic end point 24/804 (3.0) 26/726 (3.6) 0.80 (0.44–1.48) 0.485
TRACER end point 26/786 (3.3) 27/699 (3.9) 0.85 (0.47–1.54) 0.591
Noncardiac surgical bleeding 30/901 (3.3) 25/819 (3.1) 1.37 (0.76–2.45) 0.291
GUSTO moderate or severe bleeding 35/858 (4.1) 31/784 (4.0) 1.14 (0.66–1.97) 0.646
Severe bleeding 17/1146 (1.5) 12/1018 (1.2) 1.74 (0.55–5.55) 0.350
Moderate bleeding 34/1109 (0.7) 28/995 (2.8) 1.10 (0.59–2.05) 0.763
TIMI clinically significant bleeding 80/698 (11.5) 64/679 (9.4) 1.22 (0.84–1.78) 0.294
TIMI major or minor bleeding 39/850 (4.6) 28/784 (3.6) 1.22 (0.72–2.09) 0.458
Intracranial haemorrhage 4/1165 (0.3) 1/1029 (0.1) — —
GUSTO indicates Global Utilization of Strategies to Open Occluded Arteries; OR, odds ratio; TIMI, Thrombolysis In Myocardial Infarction; TRACER, Thrombin Receptor Antagonist for Clinical
Event Reduction in Acute Coronary Syndrome.
*Denominators change with removal of presurgery events.
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patients who underwent revascularization with bare-metal or
drug-eluting stents were not significantly different from those
for patients who did not undergo revascularization. No
relationship between study treatment, surgical site, and
bleeding was observed.
Long-term Outcomes in Patients With and
Without NCS
Ischemic and bleeding outcomes in NSTE ACS patients who
did and did not undergo NCS are presented in Table 3. No
significant interactions between treatment assignment and
outcomes were observed; thus, treatment groups were
pooled. The median follow-up among NCS patients (who
survived through 30 days postoperatively) and non-NCS
patients (landmarked at 30-day post-NSTE ACS survival) was
1.6 and 1.3 years, respectively. In a 30-day landmark analysis
with NCS as a time-dependent covariate, the adjusted
ischemic end point (adjusted HR 1.62, 95% CI, 1.33 to
1.97, P<0.001) and the TRACER composite end point
(adjusted HR 1.92, 95% CI, 1.62 to 2.27) were higher among
NCS patients. The incidence of GUSTO moderate or severe
bleeding (adjusted HR 5.63, 95% CI, 3.98 to 7.97, P<0.001)
(Figure 3), TIMI clinically significant bleeding (adjusted HR
3.54, 95% CI, 2.85 to 4.41, P<0.001), and TIMI major or minor
bleeding (adjusted HR 5.19, 95% CI, 3.50 to 7.71, P<0.001)
were all significantly higher in the NCS group. No significant
interaction effect was found between the subgroups (major
versus minor NCS and type of revascularization) and study
treatment assignment with the ischemic and safety end points
(results not shown).
Discussion
In this large, contemporary, international cohort of patients
undergoing NCS after an NSTE ACS with a rigorously
adjudicated clinical end point, several important findings
emerge. First, no significant differences were observed in the
30-day incidence of the primary ischemic outcome or NCS
bleeding between vorapaxar- and placebo-treated patients.
Second, early NCS after an NSTE ACS was associated with a
significant increase in adverse perioperative ischemic events.
Our findings suggest that surgery should be delayed, where
clinically appropriate, ≥30 days to minimize ischemic events
Figure 2. Adjusted associations of index ACS management, type of NCS, and surgical timing with 30-day
clinical outcomes in NCS patients. NCS bleeding was higher in patients who underwent major surgery and
in patients who underwent surgery <180 days after NSTE ACS. Ischemic events were higher in patients
who underwent NCS <30 days after NSTE ACS. ACS indicates acute coronary syndromes; GUSTO, Global
Utilization of Strategies to Open Occluded Arteries; NCS, noncardiac surgery; NSTE, non–ST-segment
elevation; TIMI, Thrombolysis In Myocardial Infarction.
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and ≥6 months to minimize bleeding events. Finally, among
30-day survivors, NCS patients had a significantly higher long-
term risk of ischemic events and bleeding compared with
patients who did not undergo NCS, irrespective of treatment
assignment.
The published incidence of NCS after an ACS or stent
implantation is 2% to 34%.1–3,13,14,21–23 This wide reported
range in these observational analyses likely reflects differ-
ences in NCS surgical procedures (major or minor), revas-
cularization strategies (bare-metal and/or drug-eluting stent),
and duration of follow-up. The present analysis, which
followed both medically treated and percutaneously revas-
cularized NSTE ACS patients for a median of 1.5 years,
found that 17.0% of patients require major or minor NCS
procedures. This finding confirms that NCS after an NSTE
ACS is common in a relatively unselected population. In
addition, the regional variations in the incidence of NCS after
an NSTE ACS observed in this study may also provide insight
into the wide difference in published NCS estimates. Our
observation that Australia/New Zealand and North American
had the highest NCS rates is similar to other published
estimates in population-based datasets, though this is the
first study to describe international geographical differences
in NCS after an NSTE ACS.1–3 Future studies may be
directed at understanding the clinical and environmental
reasons underpinning regional variations in the incidence of
NCS.
The optimal perioperative antiplatelet management strate-
gies in patients undergoing NCS after ACS remains unre-
solved. A recent major randomized trial reported that use of
aspirin increased the risk of NCS bleeding, but this trial
specifically excluded patients with recent coronary stenting or
thienopyridine use.24 Similarly, the perioperative use of
thienopyridines has been associated with increased NCS
bleeding, but hemorrhagic risks must be weighed against the
potential ischemic risks of drug discontinuation early after
coronary stenting.1,7,25–28 The protease-activated receptor 1
antagonist vorapaxar had a higher incidence of bleeding in the
overall trial population and, in this analysis, bleeding rates
were higher among patients prior to NCS; however, vorapaxar
was not associated with differences in 30-day cardiovascular
mortality, nonfatal myocardial infarction, stent thrombosis, or
urgent revascularization, or 30-day perioperative bleeding.
Importantly, 78% of the patients continued vorapaxar through
the perioperative period, and the results were similar in an on-
treatment sensitivity analysis. In addition, among the 22% of
patients who discontinued the study drug a median of
13 days preoperatively, the half-life of up to 311 hours
Table 3. Outcomes in Patients With and Without NCS
Patients Without
NCS (n=9363)
Patients With NCS (n=2202)
P Value*Events Before NCS
Events After NCS
Total ≤30 Days >30 Days
Clinical end points, n (%)
Primary ischemic end point 1230 (13.1) 255 (11.6) 253 (11.5) 80 (3.6) 173 (7.9) <0.001
TRACER end point 1348 (14.4) 327 (14.9) 240 (10.9) 96 (4.4) 144 (6.5) <0.001
All-cause mortality 367 (3.9) 1 (0.04) 201 (9.1) 34 (1.5) 167 (7.6) <0.001
Cardiovascular mortality 254 (2.7) 1 (0.04) 106 (4.8) 30 (1.4) 76 (3.4) <0.001
Myocardial infarction 819 (8.8) 237 (10.8) 146 (6.6) 68 (3.1) 78 (3.5) 0.001
Stent thrombosis 77 (0.8) 25 (1.1) 11 (0.5) 6 (0.3) 5 (0.2) 0.117
Urgent revascularization 279 (3.0) 62 (2.8) 25 (1.1) 2 (0.1) 23 (1.0) <0.001
Stroke 100 (1.1) 31 (1.4) 27 (1.2) 8 (0.4) 19 (0.9) 0.522
Safety end points, n (%)
GUSTO moderate or severe bleeding 152 (1.6) 135 (6.1) 115 (5.2) 87 (4.0) 28 (1.3) <0.001
Severe bleeding 71 (0.8) 38 (1.7) 42 (1.9) 29 (1.3) 13 (0.6) <0.001
Moderate bleeding 83 (0.9) 98 (4.5) 78 (3.5) 62 (2.8) 16 (0.7) <0.001
TIMI clinically significant bleeding 850 (9.1) 480 (21.8) 236 (10.7) 173 (7.9) 63 (2.9) 0.018
TIMI major or minor bleeding 151 (1.6) 139 (6.3) 106 (4.8) 85 (3.9) 21 (1.0) <0.001
Intracranial haemorrhage 30 (0.3) 8 (0.4) 9 (0.4) 5 (0.2) 4 (0.2) 0.520
GUSTO indicates Global Utilization of Strategies to Open Occluded Arteries; NCS, non cardiac surgery; TIMI, Thrombolysis In Myocardial Infarction; TRACER, Thrombin Receptor Antagonist
for Clinical Event Reduction in Acute Coronary Syndrome.
*P-value for the comparison of patients with events after NCS vs patients without NCS.
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suggests residual pharmacokinetic effect was likely present in
many patients. These results are consistent with an animal
study that reported no increase in bleeding time or blood loss
with vorapaxar in addition to aspirin and thienopyridine
treatment, and with the results of a secondary TRACER
analysis that reported no increase in coronary artery bypass
grafting–related major bleeding.15,29 The novel composite end
point was created to best align with clinically important
events in perioperative care; however, the results mirror those
of the TRACER end point. Our findings have implications for
patients with coronary artery disease on vorapaxar who
require NCS. Among patients requiring urgent NCS, preoper-
ative delay for the sole purpose of eliminating the drug effect
is likely unnecessary. We acknowledge the need for further
clarity regarding the perioperative management of other
antiplatelet agents and that preoperative vorapaxar manage-
ment may need to be individualized for surgical procedures
where substantial morbidity with bleeding exists (ie, neuro-
surgery).
The association between early NCS after an ACS and
adverse NCS perioperative outcomes was first described in
the prerevascularization era.4,30 A similar relationship has
been well described in patients with percutaneous revascu-
larization and has led to recommendations to delay NCS after
an ACS ≥30 days when possible.1,3,20,22,25,31–34 Our study
confirms these findings using a contemporary, international
cohort of patients with mixed revascularization strategies, and
it suggests that surgery should be delayed ≥30 days when it
is clinically appropriate. Moreover, this analysis adds impor-
tant information on perioperative bleeding. Although postop-
erative bleeding is associated with adverse outcomes across
the spectrum of surgical procedures, little is known about its
relationship with NCS timing after an NSTE ACS.24,35–37 A
recent major multicenter, randomized controlled trial reported
that aspirin before NCS increased major bleeding and, in a
post-hoc analysis, major bleeding was an independent
predictor of myocardial infarction.24 This trial did not,
however, address the risks and benefits in patients with
recent ACS. A prospective cohort of patients in France found
that timing of NCS after stenting was independently associ-
ated with the risk of hemorrhagic complications.27 With the
use of centrally adjudicated clinical end points, our findings
suggest that, if possible, surgery should to be delayed
≥6 months to minimize the risk of both NCS and spontaneous
bleeding. Postoperative ischemic events, however, were
highest within the first 30 days after NSTE ACS with relatively
balanced events thereafter. Our findings suggest that NCS
should be delayed >30 days, where clinically appropriate, to
minimize the risk of both adverse cardiac events and
hemorrhagic complications. Confirmation of this association
with other antiplatelet agents requires further investigation.
The cardiovascular and bleeding risks of NCS after an ACS
have been well described.1,38 However, little is known about
the long-term outcomes of NCS in this population. In this
study we observed a significant risk association between NCS
after NSTE ACS and both ischemic events and major bleeding.
Importantly, this analysis was landmarked to only include
patients who survived through 30 postoperative days to
minimize NCS-related events, and the Kaplan–Meier curves
for bleeding appeared to continue to separate through the
follow-up period, suggesting a long-term risk association
between NCS and NSTE ACS that extends well beyond the
traditional perioperative period. Although preoperative bleed-
ing rates were higher among vorapaxar-treated patients, no
postoperative interaction between treatment and outcomes
was observed, suggesting an independent long-term risk
association in the NCS population. We acknowledge that the
reasons underpinning these findings are beyond the scope of
this analysis and a careful evaluation of postoperative care
may be merited on the basis of these results. Clinicians ought
to carefully consider the individual patient bleeding risks and
benefits before resuming antiplatelet therapies in patients
with ACS who have undergone NCS.
Study Limitations
The limitations of the study merit consideration. The study
case report form coded for the incidence and timing of study
drug interruptions, but it did not provide detailed information
on the perioperative management of aspirin, thienopyridines,
or other cardiac medications. In addition, the current analysis
Figure 3. Long-term GUSTO moderate or severe bleeding in
NCS and non-NCS patients. Kaplan–Meier survival estimates were
obtained in patients landmarked at 30 days postsurgery or NSTE
ACS. Among 30-day survivors, there is significant long-term
bleeding among NCS patients. GUSTO, Global Utilization of
Strategies to Open Occluded Arteries; HR, hazard ratio; NCS,
noncardiac surgery; NSTE ACS, non–ST-segment elevation acute
coronary syndromes.
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was neither prespecified nor randomized. Thus, the results of
this analysis should be considered hypothesis generating.
More patients in the vorapaxar cohort of this study experi-
enced preoperative bleeding, which influences the generaliz-
ability of the study. However, no associations between
postoperative outcomes or timing of surgery were observed
in this analysis. Finally, the number of patients in the major
surgery cohort may not be adequately powered to detect a
significant result.
Conclusions
Among NSTE ACS patients undergoing NCS, we observed no
differences in perioperative ischemic or bleeding events
between vorapaxar- and placebo-treated patients. Early NCS
(≤30 days) was associated with an increased risk of adverse
perioperative ischemic events and bleeding; these findings
suggest that NCS should be delayed ≥30 days to minimize
ischemic events and delayed ≥6 months to minimize bleed-
ing. Among 30-day NCS survivors, we observed significantly
higher long-term ischemic and bleeding risk association in
patients with prior NSTE ACS. Future studies should be
directed at elucidating the relationships between concurrent
antiplatelet agents and revascularization strategies with
clinical outcomes.
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Appendices 
Table S1: List of adjusting covariates for primary and safety endpoints 
 Clinical Endpoints 
 
Safety Endpoints 
Demographics 
Age 
Sex 
Race 
 
Y 
Y 
Y 
 
Y 
Y 
Y 
Vital sign at baseline 
Weight 
Heart rate 
Diastolic blood pressure 
 
Y 
Y 
Y 
 
Y 
Y 
Y 
Lab at enrollment 
Troponin 
Creatinine clearance 
 
Y 
Y 
 
Y 
Y 
Medical history 
Hypertension 
Diabetes 
Stroke 
Angina 
Transient ischemic attack 
Heart failure 
Atrial fibrillation 
Myocardial infarction 
Peripheral arterial disease 
Tobacco use 
Percutaneous coronary 
intervention 
Coronary artery bypass grafting 
 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Disease status at enrollment 
ST-segment elevation 
New T-wave changes 
Killip class 
 
Y 
Y 
Y 
 
Y 
Y 
Y 
Baseline concomitant medications 
Thienopyridine 
Aspirin 
Glycoprotein IIb/IIIa inhibitor 
Beta-blockers 
Statin 
 
Y 
Y 
Y 
Y 
Y 
 
Y 
Y 
Y 
Y 
Y 
Table S2: Baseline characteristics of TRACER patients with and without NCS 
Characteristics All Patients 
(N=11,565) 
No Surgery 
(N=9363) 
NCS Patients 
(N=2202) 
P-value 
Age, yrs, median (IQR) 64 (58, 72) 63 (57, 71) 66 (59, 73) <0.001 
Female, n (%) 3327 (28.8) 2696 (28.8) 631 (28.7) 0.897 
Racial or ethics group, n (%)     
White 9866 (85.6) 7968 (85.3) 1898 (86.5) 0.003 
Black 275 (2.4) 221 (2.4) 54 (2.5)  
Asian 985 (8.5) 799 (8.6) 186 (8.5)  
Other 407 (3.5) 350 (3.7) 57 (2.6)  
Body weight, kg, median (IQR) 80 (70, 92) 80 (70, 92) 81.6 (70, 95) 0.001 
Treatment assignment, n (%)     
Vorapaxar 5796 (50.1) 4625 (49.4) 1171 (53.2) 0.001 
Placebo 5769 (49.9) 4738 (50.6) 1031 (46.8) 
Medical history, n (%)     
Hypertension 8112 (70.2) 6500 (69.5) 1612 (73.2) <0.001 
Dyslipidemia 7179 (62.1) 5689 (60.8) 1490 (67.7) <0.001 
Diabetes mellitus 3589 (31.0) 2790 (29.8) 799 (36.3) <0.001 
Current tobacco use 3155 (27.3) 2635 (28.2) 520 (23.6) <0.001 
Myocardial infarction 3454 (29.9) 2724 (29.1)  730 (33.1) <0.001 
Percutaneous coronary intervention 2848 (24.7) 2223 (23.8) 625 (28.4) <0.001 
Coronary artery bypass grafting 1488 (12.9) 1098 (11.7) 390 (17.7) <0.001 
Heart failure 1087 (9.4) 762 (8.1) 325 (14.8) <0.001 
Atrial fibrillation 532 (4.6) 396 (4.2) 136 (6.2) <0.001 
Stroke or transient ischemic attack 726 (6.3) 540 (5.8) 186 (8.4) <0.001 
Peripheral arterial disease 829 (7.2) 595 (6.4) 234 (10.6) <0.001 
Variables at NSTE ACS presentation     
Heart rate, bpm, median (IQR) 70 (61, 79) 70 (61, 78) 70 (61, 80) 0.997 
Systolic blood pressure, mmHg, median (IQR) 130 (118, 145) 130 (117, 145) 130 (118, 146) 0.022 
Diastolic blood pressure, mmHg, median (IQR) 75 (66, 82) 75 (67, 82) 73 (65, 82) <0.001 
Hemoglobin, g/L, median (IQR) 141 (130, 151) 141 (130, 151) 139 (126, 149) <0.001 
Creatinine clearance, µmol/L, median (IQR)  95.0 (72.7, 121.4) 96.8 (74.1, 122.6) 88.6 (66.6, 115.3) <0.001 
Positive troponin or CK-MB, n (%) 10755 (93.7) 8676 (93.4) 2079 (94.8) 0.016 
Characteristics All Patients 
(N=11,565) 
No Surgery 
(N=9363) 
NCS Patients 
(N=2202) 
P-value 
Electrocardiographic findings, n (%)     
ST-segment depression 3668 (31.7) 3019 (32.2) 649 (29.5) 0.012 
ST-segment elevation 669 (5.8) 565 (6.0) 104 (4.7) 0.018 
TIMI risk score, n (%) 
0–2 
3–4 
5–7  
 
57 (0.5) 
5994 (51.8) 
5514 (47.7) 
 
46 (0.5) 
5005 (53.4) 
4312 (46.0) 
 
11 (0.5) 
989 (0.5) 
1202 (54.6) 
 
<0.001 
Killip class total, n (%) 
I 
II 
III/IV 
11464 
10922 (95.3) 
424 (3.7) 
118 (1.0) 
9270 
8881 (95.8) 
309 (3.3) 
80 (0.9) 
2194 
2041 (93.0) 
115 (5.2) 
38 (1.7) 
 
<0.001 
NSTE ACS revascularization, n (%)     
Medical therapy 4178 (36.1) 3358 (35.9) 820 (37.2) 0.452 
Bare-metal stent 2875 (24.9) 2343 (25.0) 532 (24.2)  
Drug-eluting stent 4512 (39.0) 3662 (39.1) 850 (38.6)  
Region of enrollment, n (%)     
North America 2902 (25.1) 2148 (22.9) 754 (34.2) <0.001 
South America 698 (6.0) 610 (6.5) 88 (4.0)  
Western Europe 5324 (46.0) 4430 (47.3) 894 (40.6)  
Eastern Europe 1371 (11.9) 1195 (12.8) 176 (8.0)  
Asia 888 (7.7) 714 (7.6) 174 (7.9)  
Australian or New Zealand 382 (3.3) 266 (2.8) 116 (5.3)  
Abbreviations: CK-MB, creatinine kinase-MB; IQR, interquartile range; NCS, non-cardiac surgery; NSTE ACS, non-ST-segment elevation acute 
coronary syndrome; TIMI, Thrombolysis In Myocardial Infarction.  
Table S3: Unadjusted and adjusted vorapaxar vs. placebo outcomes between postoperative 30 days through the end of study follow-up  
Endpoints Observed Events*   Adjusted HR  
(95% CI) 
P-value 
Vorapaxar Placebo 
Primary ischemic endpoint 94/1000 (9.4) 79/867 (9.1) 1.06 (0.74–1.50) 0.767 
TRACER endpoint 78/953 (8.2) 66/826 (8.0) 1.00 (0.71-1.42) 0.987 
Non-cardiac surgical bleeding 22/1125 (2.0) 24/996 (2.4) 0.70 (0.11–4.56) 0.713 
GUSTO moderate or severe bleeding 13/1036 (1.3) 15/944 (1.6) 0.77 (0.35–1.68) 0.504 
TIMI clinically significant bleeding 33/777 (4.3) 30/772 (3.9) 1.04 (0.62–1.74) 0.877 
TIMI major or minor bleeding 12/1034 (1.2) 9/944 (1.0) 1.25 (0.49–3.19) 0.634 
*Denominators change with removal of pre-surgery events. 
Abbreviations: CI, confidence interval; GUSTO, Global Utilization of Strategies to Open Occluded Arteries; OR, odds ratio; TIMI, Thrombolysis In 
Myocardial Infarction. 
Table S4: 30-day clinical outcomes by revascularization strategy, major vs. minor surgery, and surgical timing 
 Primary 
Ischemic 
Endpoint 
 Adjusted OR 
(95% CI) 
TRACER 
Endpoint 
Adjusted OR 
(95% CI) 
Non-Cardiac 
Surgical 
Bleeding 
Adjusted OR 
(95% CI) 
GUSTO 
Moderate or 
Severe Bleeding 
Adjusted OR 
(95% CI) 
TIMI Clinically 
Significant 
Bleeding 
Adjusted OR 
(95% CI) 
TIMI Major or 
Minor Bleeding 
Adjusted O  
(95% CI) 
NSTE ACS revascularization, n (%)*             
Medical management 31 (3.8) REF 41 (5.0) REF 27 (3.3) REF 26 (3.2) REF 62 (7.6) REF 26 (3.2) REF 
Bare-metal stent 15 (2.8) 0.86 (0.43–1.72) 16 (3.0) 0.72 (0.38–1.36) 24 (4.5) 1.32 (0.72–2.42) 23 (4.3) 1.36 (0.72–2.57) 40 (7.5) 0.98 (0.61–1.56) 21 (4.0) 1.25 (0.66–2  
Drug-eluting stentϮ 34 (4.0) 1.23 (0.70–2.15) 39 (4.6) 1.09 (0.65–1.81) 30 (3.5) 1.00 (0.56–1.80) 38 (4.5) 1.50 (0.86–2.60) 71 (8.3) 1.15 (0.78–1.70) 38 (4.5) 1.48 (0.85–2  
Type of surgery, n (%)             
Minor 71 (4.1) REF 79 (4.6) REF 46 (2.7) REF 59 (3.4) REF 133 (7.7) REF 59 (3.4) REF 
Major 9 (1.9) 0.51 (0.25–1.07) 17 (3.6) 0.88 (0.50–1.55) 35 (7.4) 3.30 (2.04–5.34) 28 (5.9) 1.86 (1.14–3.03)  40 (8.4) 0.99 (0.66–1.48) 26 (5.5) 1.61 (0.97–2  
Timing of surgery after NSTE ACS, n (%)             
≤30 days 48 (11.8) REF 53 (13.0) REF 12 (3.0) REF 32 (7.9) REF 62 (15.2) REF 35 (8.6) REF 
30 to 180 days 14 (2.1) 0.16 (0.08–0.31) 22 (3.2) 0.24 (0.14–0.42) 37 (5.4) 2.34 (1.10–5.00) 30 (4.4) 0.60 (0.34–1.04) 52 (7.7) 0.48 (0.31–0.74) 24 (3.5) 0.38 (0.21–0  
180 days to 1 year 12 (2.0) 0.19 (0.10–0.37) 16 (2.7) 0.23 (0.12–0.42) 25 (4.2) 1.81 (0.82–4.02) 22 (3.7) 0.46 (0.25–0.84) 42 (7.0) 0.40 (0.26–0.64) 21 (3.5) 0.36 (0.20–0  
>1 year 6 (1.2) 0.10 (0.02–0.20) 5 (1.0) 0.07 (0.02–0.20) 7 (1.4) 0.58 (0.21–1.60) 3 (0.6) 0.07 (0.02–0.24) 17 (3.3) 0.13 (0.07–0.25) 5 (1.0) 0.20 (0.05–0  
*Refers to the index NSTE ACS. 
ϮPatients with both bare-metal and drug-eluting stents inserted were classified as drug-eluting stents. 
Abbreviations: CI, confidence interval; GUSTO, Global Utilization of Strategies to Open Occluded Arteries; NSTE ACS, non-ST-segment elevations acute coronary syndrome; OR, odds ratio; REF, 
reference; TIMI, Thrombolysis In Myocardial Infarction.  
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Table S1: List of adjusting covariates for primary and safety endpoints 
 Clinical Endpoints 
 
Safety Endpoints 
Demographics 
Age 
Sex 
Race 
 
Y 
Y 
Y 
 
Y 
Y 
Y 
Vital sign at baseline 
Weight 
Heart rate 
Diastolic blood pressure 
 
Y 
Y 
Y 
 
Y 
Y 
Y 
Lab at enrollment 
Troponin 
Creatinine clearance 
 
Y 
Y 
 
Y 
Y 
Medical history 
Hypertension 
Diabetes 
Stroke 
Angina 
Transient ischemic attack 
Heart failure 
Atrial fibrillation 
Myocardial infarction 
Peripheral arterial disease 
Tobacco use 
Percutaneous coronary 
intervention 
Coronary artery bypass grafting 
 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Disease status at enrollment 
ST-segment elevation 
New T-wave changes 
Killip class 
 
Y 
Y 
Y 
 
Y 
Y 
Y 
Baseline concomitant medications 
Thienopyridine 
Aspirin 
Glycoprotein IIb/IIIa inhibitor 
Beta-blockers 
Statin 
 
Y 
Y 
Y 
Y 
Y 
 
Y 
Y 
Y 
Y 
Y 
Table S2: Baseline characteristics of TRACER patients with and without NCS 
Characteristics All Patients 
(N=11,565) 
No Surgery 
(N=9363) 
NCS Patients 
(N=2202) 
P-value 
Age, yrs, median (IQR) 64 (58, 72) 63 (57, 71) 66 (59, 73) <0.001 
Female, n (%) 3327 (28.8) 2696 (28.8) 631 (28.7) 0.897 
Racial or ethics group, n (%)     
White 9866 (85.6) 7968 (85.3) 1898 (86.5) 0.003 
Black 275 (2.4) 221 (2.4) 54 (2.5)  
Asian 985 (8.5) 799 (8.6) 186 (8.5)  
Other 407 (3.5) 350 (3.7) 57 (2.6)  
Body weight, kg, median (IQR) 80 (70, 92) 80 (70, 92) 81.6 (70, 95) 0.001 
Treatment assignment, n (%)     
Vorapaxar 5796 (50.1) 4625 (49.4) 1171 (53.2) 0.001 
Placebo 5769 (49.9) 4738 (50.6) 1031 (46.8) 
Medical history, n (%)     
Hypertension 8112 (70.2) 6500 (69.5) 1612 (73.2) <0.001 
Dyslipidemia 7179 (62.1) 5689 (60.8) 1490 (67.7) <0.001 
Diabetes mellitus 3589 (31.0) 2790 (29.8) 799 (36.3) <0.001 
Current tobacco use 3155 (27.3) 2635 (28.2) 520 (23.6) <0.001 
Myocardial infarction 3454 (29.9) 2724 (29.1)  730 (33.1) <0.001 
Percutaneous coronary intervention 2848 (24.7) 2223 (23.8) 625 (28.4) <0.001 
Coronary artery bypass grafting 1488 (12.9) 1098 (11.7) 390 (17.7) <0.001 
Heart failure 1087 (9.4) 762 (8.1) 325 (14.8) <0.001 
Atrial fibrillation 532 (4.6) 396 (4.2) 136 (6.2) <0.001 
Stroke or transient ischemic attack 726 (6.3) 540 (5.8) 186 (8.4) <0.001 
Peripheral arterial disease 829 (7.2) 595 (6.4) 234 (10.6) <0.001 
Variables at NSTE ACS presentation     
Heart rate, bpm, median (IQR) 70 (61, 79) 70 (61, 78) 70 (61, 80) 0.997 
Systolic blood pressure, mmHg, median (IQR) 130 (118, 145) 130 (117, 145) 130 (118, 146) 0.022 
Diastolic blood pressure, mmHg, median (IQR) 75 (66, 82) 75 (67, 82) 73 (65, 82) <0.001 
Hemoglobin, g/L, median (IQR) 141 (130, 151) 141 (130, 151) 139 (126, 149) <0.001 
Creatinine clearance, µmol/L, median (IQR)  95.0 (72.7, 121.4) 96.8 (74.1, 122.6) 88.6 (66.6, 115.3) <0.001 
Positive troponin or CK-MB, n (%) 10755 (93.7) 8676 (93.4) 2079 (94.8) 0.016 
Characteristics All Patients 
(N=11,565) 
No Surgery 
(N=9363) 
NCS Patients 
(N=2202) 
P-value 
Electrocardiographic findings, n (%)     
ST-segment depression 3668 (31.7) 3019 (32.2) 649 (29.5) 0.012 
ST-segment elevation 669 (5.8) 565 (6.0) 104 (4.7) 0.018 
TIMI risk score, n (%) 
0–2 
3–4 
5–7  
 
57 (0.5) 
5994 (51.8) 
5514 (47.7) 
 
46 (0.5) 
5005 (53.4) 
4312 (46.0) 
 
11 (0.5) 
989 (0.5) 
1202 (54.6) 
 
<0.001 
Killip class total, n (%) 
I 
II 
III/IV 
11464 
10922 (95.3) 
424 (3.7) 
118 (1.0) 
9270 
8881 (95.8) 
309 (3.3) 
80 (0.9) 
2194 
2041 (93.0) 
115 (5.2) 
38 (1.7) 
 
<0.001 
NSTE ACS revascularization, n (%)     
Medical therapy 4178 (36.1) 3358 (35.9) 820 (37.2) 0.452 
Bare-metal stent 2875 (24.9) 2343 (25.0) 532 (24.2)  
Drug-eluting stent 4512 (39.0) 3662 (39.1) 850 (38.6)  
Region of enrollment, n (%)     
North America 2902 (25.1) 2148 (22.9) 754 (34.2) <0.001 
South America 698 (6.0) 610 (6.5) 88 (4.0)  
Western Europe 5324 (46.0) 4430 (47.3) 894 (40.6)  
Eastern Europe 1371 (11.9) 1195 (12.8) 176 (8.0)  
Asia 888 (7.7) 714 (7.6) 174 (7.9)  
Australian or New Zealand 382 (3.3) 266 (2.8) 116 (5.3)  
Abbreviations: CK-MB, creatinine kinase-MB; IQR, interquartile range; NCS, non-cardiac surgery; NSTE ACS, non-ST-segment elevation acute 
coronary syndrome; TIMI, Thrombolysis In Myocardial Infarction.  
Table S3: Unadjusted and adjusted vorapaxar vs. placebo outcomes between postoperative 30 days through the end of study follow-up  
Endpoints Observed Events*   Adjusted HR  
(95% CI) 
P-value 
Vorapaxar Placebo 
Primary ischemic endpoint 94/1000 (9.4) 79/867 (9.1) 1.06 (0.74–1.50) 0.767 
TRACER endpoint 78/953 (8.2) 66/826 (8.0) 1.00 (0.71-1.42) 0.987 
Non-cardiac surgical bleeding 22/1125 (2.0) 24/996 (2.4) 0.70 (0.11–4.56) 0.713 
GUSTO moderate or severe bleeding 13/1036 (1.3) 15/944 (1.6) 0.77 (0.35–1.68) 0.504 
TIMI clinically significant bleeding 33/777 (4.3) 30/772 (3.9) 1.04 (0.62–1.74) 0.877 
TIMI major or minor bleeding 12/1034 (1.2) 9/944 (1.0) 1.25 (0.49–3.19) 0.634 
*Denominators change with removal of pre-surgery events. 
Abbreviations: CI, confidence interval; GUSTO, Global Utilization of Strategies to Open Occluded Arteries; OR, odds ratio; TIMI, Thrombolysis In 
Myocardial Infarction. 
Table S4: 30-day clinical outcomes by revascularization strategy, major vs. minor surgery, and surgical timing 
 Primary 
Ischemic 
Endpoint 
 Adjusted OR 
(95% CI) 
TRACER 
Endpoint 
Adjusted OR 
(95% CI) 
Non-Cardiac 
Surgical 
Bleeding 
Adjusted OR 
(95% CI) 
GUSTO 
Moderate or 
Severe Bleeding 
Adjusted OR 
(95% CI) 
TIMI Clinically 
Significant 
Bleeding 
Adjusted OR 
(95% CI) 
TIMI Major or 
Minor Bleeding 
Adjusted O  
(95% CI) 
NSTE ACS revascularization, n (%)*             
Medical management 31 (3.8) REF 41 (5.0) REF 27 (3.3) REF 26 (3.2) REF 62 (7.6) REF 26 (3.2) REF 
Bare-metal stent 15 (2.8) 0.86 (0.43–1.72) 16 (3.0) 0.72 (0.38–1.36) 24 (4.5) 1.32 (0.72–2.42) 23 (4.3) 1.36 (0.72–2.57) 40 (7.5) 0.98 (0.61–1.56) 21 (4.0) 1.25 (0.66–2  
Drug-eluting stentϮ 34 (4.0) 1.23 (0.70–2.15) 39 (4.6) 1.09 (0.65–1.81) 30 (3.5) 1.00 (0.56–1.80) 38 (4.5) 1.50 (0.86–2.60) 71 (8.3) 1.15 (0.78–1.70) 38 (4.5) 1.48 (0.85–2  
Type of surgery, n (%)             
Minor 71 (4.1) REF 79 (4.6) REF 46 (2.7) REF 59 (3.4) REF 133 (7.7) REF 59 (3.4) REF 
Major 9 (1.9) 0.51 (0.25–1.07) 17 (3.6) 0.88 (0.50–1.55) 35 (7.4) 3.30 (2.04–5.34) 28 (5.9) 1.86 (1.14–3.03)  40 (8.4) 0.99 (0.66–1.48) 26 (5.5) 1.61 (0.97–2  
Timing of surgery after NSTE ACS, n (%)             
≤30 days 48 (11.8) REF 53 (13.0) REF 12 (3.0) REF 32 (7.9) REF 62 (15.2) REF 35 (8.6) REF 
30 to 180 days 14 (2.1) 0.16 (0.08–0.31) 22 (3.2) 0.24 (0.14–0.42) 37 (5.4) 2.34 (1.10–5.00) 30 (4.4) 0.60 (0.34–1.04) 52 (7.7) 0.48 (0.31–0.74) 24 (3.5) 0.38 (0.21–0  
180 days to 1 year 12 (2.0) 0.19 (0.10–0.37) 16 (2.7) 0.23 (0.12–0.42) 25 (4.2) 1.81 (0.82–4.02) 22 (3.7) 0.46 (0.25–0.84) 42 (7.0) 0.40 (0.26–0.64) 21 (3.5) 0.36 (0.20–0  
>1 year 6 (1.2) 0.10 (0.02–0.20) 5 (1.0) 0.07 (0.02–0.20) 7 (1.4) 0.58 (0.21–1.60) 3 (0.6) 0.07 (0.02–0.24) 17 (3.3) 0.13 (0.07–0.25) 5 (1.0) 0.20 (0.05–0  
*Refers to the index NSTE ACS. 
ϮPatients with both bare-metal and drug-eluting stents inserted were classified as drug-eluting stents. 
Abbreviations: CI, confidence interval; GUSTO, Global Utilization of Strategies to Open Occluded Arteries; NSTE ACS, non-ST-segment elevations acute coronary syndrome; OR, odds ratio; REF, 
reference; TIMI, Thrombolysis In Myocardial Infarction.  
